| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutathione Transferase | 67 | 2021 | 166 | 8.740 |
Why?
|
| Glutathione | 62 | 2021 | 343 | 7.380 |
Why?
|
| Neoplasms | 38 | 2021 | 1667 | 4.600 |
Why?
|
| ATP-Binding Cassette Transporters | 22 | 2017 | 120 | 4.510 |
Why?
|
| Antineoplastic Agents | 46 | 2021 | 1070 | 4.170 |
Why?
|
| Oxidative Stress | 29 | 2021 | 718 | 3.660 |
Why?
|
| Glutathione S-Transferase pi | 20 | 2021 | 53 | 2.870 |
Why?
|
| Reactive Oxygen Species | 23 | 2021 | 499 | 2.860 |
Why?
|
| Estramustine | 31 | 2012 | 35 | 2.730 |
Why?
|
| Isoflavones | 5 | 2020 | 31 | 2.610 |
Why?
|
| Oxidation-Reduction | 31 | 2021 | 567 | 2.500 |
Why?
|
| Isoenzymes | 21 | 2006 | 308 | 2.260 |
Why?
|
| Drug Resistance, Neoplasm | 24 | 2020 | 332 | 2.090 |
Why?
|
| Cisplatin | 15 | 2021 | 192 | 1.880 |
Why?
|
| Animals | 130 | 2021 | 20881 | 1.660 |
Why?
|
| Protein Processing, Post-Translational | 10 | 2019 | 284 | 1.620 |
Why?
|
| Unfolded Protein Response | 5 | 2021 | 70 | 1.570 |
Why?
|
| Prodrugs | 10 | 2016 | 54 | 1.530 |
Why?
|
| Prostatic Neoplasms | 22 | 2019 | 778 | 1.450 |
Why?
|
| Tumor Cells, Cultured | 46 | 2021 | 852 | 1.420 |
Why?
|
| Antioxidants | 9 | 2021 | 304 | 1.400 |
Why?
|
| Drug Discovery | 3 | 2017 | 94 | 1.400 |
Why?
|
| Signal Transduction | 16 | 2018 | 2689 | 1.360 |
Why?
|
| Humans | 176 | 2021 | 68618 | 1.310 |
Why?
|
| Glutathione Disulfide | 8 | 2012 | 31 | 1.290 |
Why?
|
| Nitric Oxide | 9 | 2021 | 382 | 1.240 |
Why?
|
| Azo Compounds | 8 | 2010 | 33 | 1.240 |
Why?
|
| Oxidoreductases | 8 | 2008 | 117 | 1.230 |
Why?
|
| Cysteine | 4 | 2018 | 112 | 1.180 |
Why?
|
| Drug Resistance | 35 | 2011 | 223 | 1.060 |
Why?
|
| Mice | 56 | 2021 | 8474 | 1.040 |
Why?
|
| Lung Neoplasms | 9 | 2019 | 1173 | 1.030 |
Why?
|
| Gene Expression Profiling | 8 | 2004 | 498 | 0.980 |
Why?
|
| Ethacrynic Acid | 15 | 1998 | 16 | 0.960 |
Why?
|
| Gene Expression Regulation, Enzymologic | 8 | 2014 | 282 | 0.930 |
Why?
|
| NF-E2-Related Factor 2 | 5 | 2021 | 110 | 0.900 |
Why?
|
| Nitrogen Mustard Compounds | 16 | 1992 | 16 | 0.890 |
Why?
|
| Sulfhydryl Compounds | 7 | 2014 | 73 | 0.880 |
Why?
|
| Bone Marrow | 5 | 2014 | 168 | 0.870 |
Why?
|
| Hypercholesterolemia | 3 | 2017 | 86 | 0.860 |
Why?
|
| 4-Aminobenzoic Acid | 9 | 2021 | 30 | 0.840 |
Why?
|
| Cell Survival | 18 | 2016 | 901 | 0.840 |
Why?
|
| Cell Line, Tumor | 15 | 2021 | 1851 | 0.840 |
Why?
|
| Selenoproteins | 3 | 2019 | 4 | 0.800 |
Why?
|
| para-Aminobenzoates | 8 | 2010 | 27 | 0.790 |
Why?
|
| Energy Metabolism | 3 | 2020 | 222 | 0.780 |
Why?
|
| Serpins | 3 | 2019 | 205 | 0.780 |
Why?
|
| Cell Movement | 3 | 2014 | 630 | 0.780 |
Why?
|
| Apoptosis | 12 | 2020 | 1641 | 0.780 |
Why?
|
| Selenium | 2 | 2017 | 36 | 0.770 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 940 | 0.770 |
Why?
|
| NADP | 2 | 2020 | 39 | 0.750 |
Why?
|
| Mice, Knockout | 15 | 2018 | 1692 | 0.750 |
Why?
|
| Mitochondria | 5 | 2021 | 643 | 0.750 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2020 | 9 | 0.730 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2020 | 10 | 0.720 |
Why?
|
| Alzheimer Disease | 6 | 2017 | 565 | 0.720 |
Why?
|
| Gene Expression | 8 | 2004 | 770 | 0.690 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 48 | 0.670 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 40 | 0.670 |
Why?
|
| Neoplasm Proteins | 10 | 2008 | 307 | 0.660 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2004 | 320 | 0.660 |
Why?
|
| Molecular Sequence Data | 20 | 2012 | 1447 | 0.640 |
Why?
|
| Glucose | 1 | 2020 | 307 | 0.630 |
Why?
|
| Cell Line | 28 | 2016 | 1752 | 0.600 |
Why?
|
| Lactoylglutathione Lyase | 6 | 1999 | 7 | 0.600 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 148 | 0.590 |
Why?
|
| Ovarian Neoplasms | 6 | 2009 | 267 | 0.590 |
Why?
|
| Transcription Factors | 5 | 2004 | 753 | 0.590 |
Why?
|
| HL-60 Cells | 12 | 2010 | 50 | 0.580 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 3 | 2012 | 20 | 0.570 |
Why?
|
| Estrogens | 2 | 2012 | 173 | 0.560 |
Why?
|
| Cytotoxins | 5 | 2005 | 23 | 0.550 |
Why?
|
| Boronic Acids | 1 | 2016 | 40 | 0.550 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 29 | 0.550 |
Why?
|
| Colonic Neoplasms | 10 | 1996 | 299 | 0.550 |
Why?
|
| DNA-Binding Proteins | 7 | 2003 | 700 | 0.540 |
Why?
|
| Protein S | 1 | 2016 | 9 | 0.540 |
Why?
|
| Cell Proliferation | 8 | 2018 | 1174 | 0.540 |
Why?
|
| Enzyme Inhibitors | 6 | 2019 | 659 | 0.540 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1034 | 0.530 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 4 | 1998 | 12 | 0.530 |
Why?
|
| Pharmacology, Clinical | 1 | 2016 | 13 | 0.530 |
Why?
|
| Microtubules | 11 | 1992 | 104 | 0.520 |
Why?
|
| Protein Binding | 12 | 2021 | 1027 | 0.520 |
Why?
|
| Health Status Disparities | 1 | 2019 | 326 | 0.520 |
Why?
|
| Drug Resistance, Multiple | 8 | 2007 | 56 | 0.510 |
Why?
|
| Cell Death | 4 | 2012 | 329 | 0.500 |
Why?
|
| Selenium Compounds | 3 | 2017 | 14 | 0.490 |
Why?
|
| Biomarkers | 2 | 2019 | 1593 | 0.480 |
Why?
|
| Nitrosourea Compounds | 13 | 1989 | 16 | 0.480 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 65 | 0.470 |
Why?
|
| Protein Disulfide-Isomerases | 2 | 2016 | 27 | 0.470 |
Why?
|
| Glutamate-Cysteine Ligase | 6 | 2000 | 16 | 0.460 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2005 | 99 | 0.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2012 | 300 | 0.460 |
Why?
|
| Transfection | 13 | 2005 | 782 | 0.460 |
Why?
|
| Carcinoma 256, Walker | 12 | 1993 | 12 | 0.460 |
Why?
|
| Polymerase Chain Reaction | 7 | 2008 | 492 | 0.450 |
Why?
|
| Ostreidae | 3 | 1998 | 7 | 0.450 |
Why?
|
| Transcription, Genetic | 8 | 2003 | 562 | 0.440 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 158 | 0.440 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 508 | 0.430 |
Why?
|
| Amino Acid Sequence | 13 | 2012 | 1083 | 0.430 |
Why?
|
| Colon | 5 | 1994 | 168 | 0.430 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2012 | 4 | 0.430 |
Why?
|
| Alcohol Oxidoreductases | 5 | 1998 | 31 | 0.420 |
Why?
|
| Mucositis | 1 | 2012 | 9 | 0.420 |
Why?
|
| Neoplastic Stem Cells | 4 | 2021 | 84 | 0.420 |
Why?
|
| S100 Proteins | 1 | 2012 | 42 | 0.420 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 22 | 0.420 |
Why?
|
| Drug Combinations | 7 | 2012 | 304 | 0.410 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2004 | 250 | 0.410 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 2012 | 7 | 0.410 |
Why?
|
| Penis | 1 | 2012 | 25 | 0.410 |
Why?
|
| DNA | 15 | 1999 | 597 | 0.400 |
Why?
|
| Chlorambucil | 10 | 1993 | 17 | 0.400 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 61 | 0.390 |
Why?
|
| Calcium | 3 | 2016 | 929 | 0.390 |
Why?
|
| Oncogenes | 1 | 2011 | 71 | 0.380 |
Why?
|
| Cell Division | 12 | 2004 | 541 | 0.380 |
Why?
|
| Base Sequence | 11 | 2008 | 1015 | 0.380 |
Why?
|
| Nitric Oxide Synthase | 2 | 2014 | 163 | 0.380 |
Why?
|
| Inactivation, Metabolic | 7 | 2011 | 28 | 0.380 |
Why?
|
| 3T3 Cells | 11 | 2005 | 124 | 0.370 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 8 | 2010 | 140 | 0.370 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2005 | 82 | 0.370 |
Why?
|
| Immune System | 1 | 2010 | 63 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 4 | 2003 | 615 | 0.360 |
Why?
|
| Protective Agents | 1 | 2010 | 36 | 0.360 |
Why?
|
| DNA Helicases | 2 | 2002 | 64 | 0.360 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 235 | 0.360 |
Why?
|
| Drug Screening Assays, Antitumor | 8 | 2019 | 111 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2014 | 756 | 0.350 |
Why?
|
| Nuclear Proteins | 6 | 2002 | 271 | 0.350 |
Why?
|
| Seizures | 1 | 2012 | 279 | 0.350 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 13 | 2006 | 272 | 0.350 |
Why?
|
| Molecular Structure | 6 | 2011 | 397 | 0.350 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 301 | 0.350 |
Why?
|
| Myelin Sheath | 2 | 2008 | 115 | 0.340 |
Why?
|
| Homeostasis | 6 | 2021 | 291 | 0.340 |
Why?
|
| Radiation-Protective Agents | 2 | 2019 | 16 | 0.340 |
Why?
|
| Receptors, LDL | 2 | 2012 | 72 | 0.340 |
Why?
|
| Doxorubicin | 6 | 2016 | 231 | 0.340 |
Why?
|
| Gene Expression Regulation | 8 | 2016 | 1293 | 0.330 |
Why?
|
| Nitric Oxide Donors | 2 | 2010 | 54 | 0.320 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 475 | 0.320 |
Why?
|
| Cholesterol | 3 | 2012 | 331 | 0.320 |
Why?
|
| Bortezomib | 2 | 2020 | 45 | 0.320 |
Why?
|
| Molecular Mimicry | 1 | 2008 | 13 | 0.320 |
Why?
|
| Mechlorethamine | 7 | 2000 | 9 | 0.320 |
Why?
|
| Nitroso Compounds | 2 | 2004 | 16 | 0.310 |
Why?
|
| Receptors, CXCR4 | 2 | 2021 | 48 | 0.310 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 332 | 0.310 |
Why?
|
| Cell Physiological Phenomena | 1 | 2008 | 19 | 0.310 |
Why?
|
| Adenosine Triphosphatases | 2 | 2005 | 83 | 0.310 |
Why?
|
| Azides | 4 | 1999 | 56 | 0.310 |
Why?
|
| Nervous System Diseases | 2 | 2011 | 142 | 0.300 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2006 | 109 | 0.300 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 92 | 0.300 |
Why?
|
| Enzyme Activation | 9 | 2005 | 791 | 0.300 |
Why?
|
| Eukaryotic Cells | 2 | 2006 | 7 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 170 | 0.290 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2008 | 67 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2000 | 57 | 0.290 |
Why?
|
| Models, Molecular | 4 | 2021 | 546 | 0.290 |
Why?
|
| Anticarcinogenic Agents | 2 | 2004 | 52 | 0.290 |
Why?
|
| Protein Interaction Mapping | 3 | 2016 | 62 | 0.280 |
Why?
|
| Tremor | 1 | 2006 | 16 | 0.280 |
Why?
|
| RNA, Messenger | 11 | 2005 | 1664 | 0.280 |
Why?
|
| Financing, Government | 1 | 2006 | 16 | 0.280 |
Why?
|
| Lung | 4 | 2016 | 849 | 0.280 |
Why?
|
| Male | 43 | 2021 | 37321 | 0.280 |
Why?
|
| Neoplasms, Experimental | 5 | 2005 | 118 | 0.280 |
Why?
|
| Psychomotor Agitation | 1 | 2006 | 63 | 0.270 |
Why?
|
| Paclitaxel | 4 | 2001 | 140 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2005 | 231 | 0.270 |
Why?
|
| Mitosis | 7 | 1997 | 76 | 0.270 |
Why?
|
| Research Support as Topic | 1 | 2006 | 58 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 710 | 0.270 |
Why?
|
| Gene Amplification | 2 | 2004 | 71 | 0.270 |
Why?
|
| Immediate-Early Proteins | 2 | 2003 | 63 | 0.270 |
Why?
|
| DNA, Complementary | 5 | 2001 | 251 | 0.270 |
Why?
|
| Models, Biological | 3 | 2016 | 981 | 0.270 |
Why?
|
| Central Nervous System | 1 | 2006 | 107 | 0.270 |
Why?
|
| Carcinoma | 4 | 1998 | 215 | 0.260 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2019 | 268 | 0.260 |
Why?
|
| Tubulin | 5 | 1998 | 60 | 0.260 |
Why?
|
| Drugs, Investigational | 1 | 2005 | 18 | 0.260 |
Why?
|
| Carrier Proteins | 3 | 2020 | 597 | 0.260 |
Why?
|
| Cloning, Molecular | 7 | 2005 | 357 | 0.260 |
Why?
|
| Mice, SCID | 7 | 2021 | 238 | 0.260 |
Why?
|
| DNA Primers | 6 | 2008 | 302 | 0.250 |
Why?
|
| Binding Sites | 9 | 2003 | 631 | 0.250 |
Why?
|
| Biological Transport | 7 | 2006 | 210 | 0.250 |
Why?
|
| Protein Kinases | 2 | 2005 | 122 | 0.250 |
Why?
|
| Fibroblasts | 3 | 2005 | 902 | 0.250 |
Why?
|
| Rats | 24 | 2011 | 5300 | 0.240 |
Why?
|
| Hematopoiesis | 2 | 2018 | 108 | 0.240 |
Why?
|
| Metallothionein | 2 | 2003 | 20 | 0.240 |
Why?
|
| MAP Kinase Signaling System | 3 | 2003 | 247 | 0.230 |
Why?
|
| Cells, Cultured | 13 | 2014 | 2673 | 0.230 |
Why?
|
| Carotenoids | 1 | 2004 | 45 | 0.230 |
Why?
|
| Allyl Compounds | 1 | 2004 | 29 | 0.230 |
Why?
|
| Tissue Distribution | 5 | 2012 | 282 | 0.230 |
Why?
|
| Phytosterols | 1 | 2003 | 8 | 0.230 |
Why?
|
| Oxidants | 2 | 2021 | 48 | 0.230 |
Why?
|
| Trace Elements | 1 | 2003 | 23 | 0.230 |
Why?
|
| Antigens, Nuclear | 3 | 2002 | 24 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 290 | 0.230 |
Why?
|
| DNA, Neoplasm | 8 | 1992 | 95 | 0.230 |
Why?
|
| Peroxiredoxin VI | 2 | 2014 | 18 | 0.220 |
Why?
|
| Vanadates | 1 | 2003 | 12 | 0.220 |
Why?
|
| Hydroquinones | 1 | 2003 | 15 | 0.220 |
Why?
|
| Zinc | 1 | 2003 | 73 | 0.220 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 49 | 0.220 |
Why?
|
| Myeloid Cells | 1 | 2003 | 57 | 0.220 |
Why?
|
| Liver | 8 | 2016 | 1118 | 0.220 |
Why?
|
| Cytoprotection | 2 | 2012 | 39 | 0.220 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 1174 | 0.220 |
Why?
|
| Lipoproteins, LDL | 2 | 2012 | 343 | 0.220 |
Why?
|
| Sp1 Transcription Factor | 1 | 2003 | 21 | 0.220 |
Why?
|
| Carcinogens | 1 | 2003 | 86 | 0.220 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 138 | 0.220 |
Why?
|
| Genetic Techniques | 1 | 2002 | 32 | 0.210 |
Why?
|
| HT29 Cells | 3 | 2000 | 42 | 0.210 |
Why?
|
| Kinetics | 8 | 2014 | 1047 | 0.210 |
Why?
|
| Glutamine | 1 | 2002 | 45 | 0.210 |
Why?
|
| Zebrafish | 2 | 2021 | 187 | 0.210 |
Why?
|
| Estradiol | 4 | 2012 | 176 | 0.210 |
Why?
|
| Hydrogen Peroxide | 5 | 2019 | 168 | 0.210 |
Why?
|
| Copper | 1 | 2003 | 149 | 0.200 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 5 | 0.200 |
Why?
|
| Disease | 4 | 2003 | 41 | 0.200 |
Why?
|
| Arginine | 1 | 2002 | 102 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2004 | 163 | 0.200 |
Why?
|
| Membrane Glycoproteins | 3 | 2011 | 370 | 0.200 |
Why?
|
| Immunoblotting | 3 | 2010 | 254 | 0.200 |
Why?
|
| Genetic Variation | 1 | 2003 | 220 | 0.200 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2020 | 93 | 0.200 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2021 | 7 | 0.200 |
Why?
|
| Organoselenium Compounds | 2 | 2019 | 17 | 0.200 |
Why?
|
| Mercaptoethylamines | 1 | 2001 | 3 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 1999 | 82 | 0.190 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 22 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2017 | 137 | 0.190 |
Why?
|
| Protein Transport | 2 | 2016 | 280 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 90 | 0.190 |
Why?
|
| Tunicamycin | 1 | 2021 | 10 | 0.190 |
Why?
|
| Flow Cytometry | 5 | 2008 | 489 | 0.190 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2021 | 6 | 0.190 |
Why?
|
| Larva | 1 | 2021 | 39 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 2006 | 56 | 0.190 |
Why?
|
| CHO Cells | 4 | 2005 | 161 | 0.190 |
Why?
|
| Cricetinae | 4 | 2005 | 262 | 0.190 |
Why?
|
| Hemoglobins | 2 | 2018 | 120 | 0.190 |
Why?
|
| Female | 32 | 2021 | 38074 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2012 | 102 | 0.180 |
Why?
|
| Zebrafish Proteins | 1 | 2021 | 100 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2020 | 111 | 0.180 |
Why?
|
| Actins | 3 | 2012 | 249 | 0.180 |
Why?
|
| DNA-Activated Protein Kinase | 4 | 2002 | 5 | 0.180 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 1986 | 114 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 2791 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 175 | 0.170 |
Why?
|
| Glutathione Peroxidase | 3 | 2014 | 39 | 0.170 |
Why?
|
| NF-E2 Transcription Factor | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hormesis | 1 | 2019 | 2 | 0.170 |
Why?
|
| Glutamic Acid | 1 | 2002 | 332 | 0.170 |
Why?
|
| HeLa Cells | 10 | 2001 | 237 | 0.170 |
Why?
|
| Substrate Specificity | 6 | 2001 | 234 | 0.170 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.170 |
Why?
|
| Benzene Derivatives | 1 | 2019 | 12 | 0.170 |
Why?
|
| Enzyme Induction | 6 | 2016 | 119 | 0.170 |
Why?
|
| Multidrug Resistance-Associated Proteins | 5 | 2004 | 24 | 0.170 |
Why?
|
| Gamma Rays | 1 | 2019 | 64 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 26 | 0.170 |
Why?
|
| Structure-Activity Relationship | 7 | 2009 | 420 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 5 | 1994 | 114 | 0.160 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2005 | 73 | 0.160 |
Why?
|
| Microtubule Proteins | 2 | 1997 | 4 | 0.160 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 1536 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 1753 | 0.160 |
Why?
|
| Blotting, Western | 6 | 2005 | 954 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2019 | 112 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2019 | 84 | 0.160 |
Why?
|
| Nucleoproteins | 4 | 1986 | 6 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2012 | 1745 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2008 | 1200 | 0.150 |
Why?
|
| Kidney | 5 | 2021 | 945 | 0.150 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2011 | 115 | 0.150 |
Why?
|
| Phenanthrenes | 1 | 2017 | 18 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2005 | 376 | 0.150 |
Why?
|
| Diterpenes | 1 | 2017 | 42 | 0.150 |
Why?
|
| Glutaredoxins | 2 | 2016 | 12 | 0.150 |
Why?
|
| Intestinal Mucosa | 4 | 2012 | 219 | 0.150 |
Why?
|
| Cell Membrane | 4 | 2012 | 525 | 0.150 |
Why?
|
| In Vitro Techniques | 9 | 1997 | 765 | 0.150 |
Why?
|
| I-kappa B Kinase | 2 | 2016 | 40 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 65 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 41 | 0.150 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 2 | 1994 | 8 | 0.140 |
Why?
|
| Cell Nucleus | 4 | 1986 | 305 | 0.140 |
Why?
|
| Pyrazines | 1 | 2016 | 46 | 0.140 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 69 | 0.140 |
Why?
|
| Affinity Labels | 3 | 1996 | 66 | 0.140 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 76 | 0.140 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2006 | 13 | 0.140 |
Why?
|
| Kidney Diseases | 2 | 2009 | 307 | 0.130 |
Why?
|
| Catalytic Domain | 2 | 2009 | 99 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2018 | 201 | 0.130 |
Why?
|
| Extracellular Space | 1 | 2016 | 121 | 0.130 |
Why?
|
| Biological Availability | 4 | 2004 | 79 | 0.130 |
Why?
|
| Glycolysis | 1 | 2016 | 79 | 0.130 |
Why?
|
| Macrophages | 2 | 2012 | 647 | 0.130 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 12 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2016 | 18 | 0.130 |
Why?
|
| Diet | 3 | 2004 | 514 | 0.130 |
Why?
|
| Free Radicals | 1 | 2016 | 65 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2010 | 107 | 0.130 |
Why?
|
| Estrone | 2 | 2012 | 9 | 0.130 |
Why?
|
| MCF-7 Cells | 4 | 2019 | 80 | 0.130 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 52 | 0.130 |
Why?
|
| Lomustine | 5 | 1986 | 10 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 369 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 1992 | 468 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 1998 | 332 | 0.130 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 99 | 0.130 |
Why?
|
| Free Radical Scavengers | 2 | 2014 | 112 | 0.130 |
Why?
|
| Blood Proteins | 1 | 1995 | 94 | 0.120 |
Why?
|
| Risk Factors | 3 | 2019 | 5731 | 0.120 |
Why?
|
| Biomimetics | 1 | 2014 | 17 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2014 | 19 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 446 | 0.120 |
Why?
|
| Time Factors | 7 | 2012 | 4655 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 627 | 0.120 |
Why?
|
| Cricetulus | 2 | 2005 | 98 | 0.120 |
Why?
|
| RNA Interference | 2 | 2017 | 266 | 0.120 |
Why?
|
| Drug Compounding | 1 | 2014 | 34 | 0.120 |
Why?
|
| Alkylating Agents | 3 | 2000 | 15 | 0.120 |
Why?
|
| Cytosol | 5 | 1994 | 123 | 0.120 |
Why?
|
| Polyesters | 1 | 2014 | 55 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 51 | 0.120 |
Why?
|
| Sulfonamides | 2 | 2016 | 141 | 0.120 |
Why?
|
| Phosphotransferases | 2 | 2006 | 16 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 3 | 2001 | 61 | 0.120 |
Why?
|
| Chromatin | 5 | 1982 | 76 | 0.120 |
Why?
|
| DNA Damage | 2 | 1998 | 190 | 0.120 |
Why?
|
| Survival Rate | 2 | 2008 | 1056 | 0.120 |
Why?
|
| Cell Cycle Proteins | 2 | 2008 | 230 | 0.120 |
Why?
|
| Phenotype | 4 | 2006 | 947 | 0.110 |
Why?
|
| Ligands | 2 | 2014 | 317 | 0.110 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2004 | 33 | 0.110 |
Why?
|
| Metaphase | 2 | 1991 | 12 | 0.110 |
Why?
|
| United States | 3 | 2019 | 7367 | 0.110 |
Why?
|
| Peroxidases | 1 | 2013 | 28 | 0.110 |
Why?
|
| Up-Regulation | 4 | 2016 | 682 | 0.110 |
Why?
|
| Mutation | 3 | 2012 | 1213 | 0.110 |
Why?
|
| Glutathione Reductase | 4 | 2010 | 17 | 0.110 |
Why?
|
| Nitrogen | 1 | 2013 | 57 | 0.110 |
Why?
|
| Tumor Stem Cell Assay | 6 | 1998 | 30 | 0.110 |
Why?
|
| Databases, Factual | 1 | 1996 | 622 | 0.110 |
Why?
|
| Protein Conformation | 3 | 2016 | 362 | 0.110 |
Why?
|
| NF-kappa B | 4 | 2016 | 432 | 0.110 |
Why?
|
| Down-Regulation | 3 | 2011 | 447 | 0.110 |
Why?
|
| Cell Cycle | 4 | 2003 | 312 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2004 | 2077 | 0.110 |
Why?
|
| Health | 2 | 2002 | 26 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 207 | 0.110 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2012 | 15 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Aged | 10 | 2019 | 14862 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 48 | 0.100 |
Why?
|
| Molecular Weight | 6 | 1993 | 358 | 0.100 |
Why?
|
| Penile Erection | 1 | 2012 | 18 | 0.100 |
Why?
|
| Fas Ligand Protein | 1 | 2012 | 64 | 0.100 |
Why?
|
| Biotransformation | 1 | 2012 | 69 | 0.100 |
Why?
|
| fas Receptor | 1 | 2012 | 54 | 0.100 |
Why?
|
| Cyclins | 2 | 2003 | 50 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2002 | 381 | 0.100 |
Why?
|
| Gastric Mucosa | 1 | 2012 | 77 | 0.100 |
Why?
|
| Asthma | 1 | 2016 | 345 | 0.100 |
Why?
|
| Exons | 2 | 2004 | 122 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2003 | 97 | 0.100 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 138 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 132 | 0.100 |
Why?
|
| Phenols | 2 | 2002 | 73 | 0.100 |
Why?
|
| Cattle | 4 | 1998 | 475 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 139 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 59 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2014 | 296 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2012 | 324 | 0.100 |
Why?
|
| Drosophila Proteins | 1 | 2011 | 44 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.100 |
Why?
|
| Anaphase | 1 | 1991 | 3 | 0.100 |
Why?
|
| DNA Repair | 5 | 2021 | 127 | 0.100 |
Why?
|
| Aortic Diseases | 1 | 2012 | 113 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 226 | 0.100 |
Why?
|
| Ku Autoantigen | 2 | 2002 | 5 | 0.090 |
Why?
|
| Inflammation | 2 | 2016 | 1030 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2010 | 617 | 0.090 |
Why?
|
| Aorta | 1 | 2012 | 316 | 0.090 |
Why?
|
| Proteins | 2 | 2005 | 474 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2014 | 268 | 0.090 |
Why?
|
| Breast | 1 | 1991 | 137 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 167 | 0.090 |
Why?
|
| Lysosomes | 2 | 2012 | 136 | 0.090 |
Why?
|
| Adaptation, Physiological | 3 | 2011 | 189 | 0.090 |
Why?
|
| Reactive Nitrogen Species | 1 | 2010 | 32 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2012 | 328 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 201 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 92 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2012 | 204 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 44 | 0.090 |
Why?
|
| Smoking | 2 | 2016 | 1452 | 0.090 |
Why?
|
| Organophosphorus Compounds | 1 | 1989 | 13 | 0.090 |
Why?
|
| Hydrocortisone | 2 | 1982 | 291 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2004 | 95 | 0.090 |
Why?
|
| Microsomes | 1 | 1989 | 31 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 306 | 0.080 |
Why?
|
| Protein Folding | 1 | 2009 | 82 | 0.080 |
Why?
|
| Drug Tolerance | 2 | 2008 | 80 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 306 | 0.080 |
Why?
|
| Blotting, Northern | 3 | 2001 | 189 | 0.080 |
Why?
|
| Alkylation | 9 | 1987 | 26 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2014 | 35 | 0.080 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.080 |
Why?
|
| Prostate | 2 | 1998 | 116 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 848 | 0.080 |
Why?
|
| Daunorubicin | 2 | 1999 | 20 | 0.080 |
Why?
|
| Microscopy, Electron | 5 | 1991 | 351 | 0.080 |
Why?
|
| Epoprostenol | 1 | 1988 | 71 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 274 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 1990 | 329 | 0.080 |
Why?
|
| Sequence Deletion | 2 | 1999 | 89 | 0.080 |
Why?
|
| Motor Activity | 1 | 2011 | 621 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1033 | 0.080 |
Why?
|
| Streptozocin | 4 | 1986 | 34 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2010 | 384 | 0.070 |
Why?
|
| Proteomics | 1 | 2009 | 246 | 0.070 |
Why?
|
| gamma-Glutamyltransferase | 3 | 2009 | 37 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 231 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.070 |
Why?
|
| Sterols | 1 | 2007 | 13 | 0.070 |
Why?
|
| Drug Interactions | 3 | 2003 | 289 | 0.070 |
Why?
|
| Hormones | 1 | 1987 | 42 | 0.070 |
Why?
|
| Methyltransferases | 1 | 1986 | 19 | 0.070 |
Why?
|
| Leukotriene C4 | 2 | 2004 | 7 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1999 | 282 | 0.070 |
Why?
|
| Cocaine | 1 | 2011 | 555 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2004 | 134 | 0.070 |
Why?
|
| Cytokines | 1 | 2010 | 866 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 33 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 236 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 161 | 0.070 |
Why?
|
| Dansyl Compounds | 1 | 1985 | 5 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 434 | 0.070 |
Why?
|
| Brain | 2 | 2012 | 2176 | 0.070 |
Why?
|
| Nucleoside Diphosphate Sugars | 1 | 1985 | 2 | 0.060 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 1985 | 4 | 0.060 |
Why?
|
| Isoelectric Focusing | 3 | 1994 | 42 | 0.060 |
Why?
|
| beta-Cyclodextrins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Clone Cells | 1 | 2005 | 67 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2006 | 102 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2003 | 195 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 58 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 334 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 86 | 0.060 |
Why?
|
| Isoelectric Point | 3 | 1991 | 9 | 0.060 |
Why?
|
| Protein Biosynthesis | 3 | 1994 | 181 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 1985 | 86 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 196 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2004 | 2 | 0.060 |
Why?
|
| Niemann-Pick Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Rabbits | 1 | 2005 | 509 | 0.060 |
Why?
|
| Mitoxantrone | 1 | 2004 | 7 | 0.060 |
Why?
|
| Androstenes | 1 | 2004 | 6 | 0.060 |
Why?
|
| Esterification | 1 | 2004 | 25 | 0.060 |
Why?
|
| Amidines | 1 | 2004 | 7 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2001 | 411 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 53 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2004 | 14 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2001 | 71 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2004 | 29 | 0.060 |
Why?
|
| Methionine | 1 | 2004 | 36 | 0.060 |
Why?
|
| Anthracenes | 1 | 2003 | 26 | 0.060 |
Why?
|
| Sulfides | 1 | 2004 | 43 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2003 | 11 | 0.060 |
Why?
|
| Copper-transporting ATPases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 160 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 74 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 71 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2006 | 470 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2004 | 93 | 0.060 |
Why?
|
| Artemisinins | 1 | 2003 | 2 | 0.060 |
Why?
|
| Mammals | 1 | 2003 | 47 | 0.060 |
Why?
|
| Biopsy | 1 | 2005 | 540 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 112 | 0.060 |
Why?
|
| Progesterone | 1 | 2004 | 115 | 0.060 |
Why?
|
| Middle Aged | 10 | 2021 | 21147 | 0.060 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2003 | 22 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2003 | 41 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2003 | 23 | 0.060 |
Why?
|
| CD11b Antigen | 1 | 2003 | 47 | 0.060 |
Why?
|
| Drug Synergism | 4 | 1996 | 260 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 1 | 2003 | 36 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2003 | 38 | 0.060 |
Why?
|
| Sp4 Transcription Factor | 1 | 2003 | 3 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2003 | 4 | 0.050 |
Why?
|
| 5' Flanking Region | 1 | 2003 | 8 | 0.050 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 11 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2004 | 109 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 29 | 0.050 |
Why?
|
| Drosophila | 1 | 2003 | 37 | 0.050 |
Why?
|
| Sex Factors | 2 | 2008 | 1266 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2003 | 42 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 88 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2000 | 129 | 0.050 |
Why?
|
| Piperazines | 1 | 2004 | 206 | 0.050 |
Why?
|
| RNA | 2 | 1994 | 171 | 0.050 |
Why?
|
| Dimerization | 1 | 2002 | 99 | 0.050 |
Why?
|
| Genotype | 1 | 2005 | 786 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2004 | 120 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 237 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 786 | 0.050 |
Why?
|
| Alleles | 2 | 2014 | 386 | 0.050 |
Why?
|
| Phytoestrogens | 1 | 2002 | 5 | 0.050 |
Why?
|
| Methionine Sulfoximine | 3 | 1995 | 7 | 0.050 |
Why?
|
| Fabaceae | 1 | 2002 | 12 | 0.050 |
Why?
|
| Lignans | 1 | 2002 | 10 | 0.050 |
Why?
|
| Diethylstilbestrol | 1 | 2002 | 45 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2002 | 18 | 0.050 |
Why?
|
| DDT | 1 | 2002 | 19 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 1992 | 4848 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 194 | 0.050 |
Why?
|
| Oligopeptides | 2 | 1999 | 152 | 0.050 |
Why?
|
| Karyopherins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Fishes | 3 | 1987 | 77 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2223 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 55 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 24 | 0.050 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2001 | 12 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 28 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 57 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2002 | 155 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2001 | 742 | 0.050 |
Why?
|
| Drug Design | 1 | 2002 | 107 | 0.050 |
Why?
|
| Mathematics | 1 | 2001 | 83 | 0.050 |
Why?
|
| Proteome | 1 | 2002 | 87 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2001 | 25 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 37 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 92 | 0.050 |
Why?
|
| Health Status | 1 | 2004 | 429 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2001 | 165 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2012 | 326 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 112 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 3 | 1998 | 261 | 0.050 |
Why?
|
| Glutathione Synthase | 2 | 2003 | 3 | 0.050 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2002 | 147 | 0.050 |
Why?
|
| Aging | 2 | 2003 | 911 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 337 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2020 | 97 | 0.040 |
Why?
|
| Polymers | 1 | 2002 | 244 | 0.040 |
Why?
|
| Dinitrophenols | 1 | 1999 | 4 | 0.040 |
Why?
|
| Zinc Compounds | 1 | 1999 | 9 | 0.040 |
Why?
|
| Environmental Pollutants | 1 | 2002 | 180 | 0.040 |
Why?
|
| Introns | 1 | 1999 | 68 | 0.040 |
Why?
|
| Chlorides | 1 | 1999 | 68 | 0.040 |
Why?
|
| Genes | 1 | 1999 | 86 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 71 | 0.040 |
Why?
|
| Catalysis | 1 | 1999 | 123 | 0.040 |
Why?
|
| NAD | 2 | 1993 | 73 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 68 | 0.040 |
Why?
|
| Tritium | 2 | 1995 | 101 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 208 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1999 | 150 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 567 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1998 | 25 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1998 | 67 | 0.040 |
Why?
|
| Half-Life | 2 | 1995 | 96 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 48 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1998 | 23 | 0.040 |
Why?
|
| Thymidine | 1 | 1978 | 32 | 0.040 |
Why?
|
| Vinblastine | 2 | 1995 | 40 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 1996 | 314 | 0.040 |
Why?
|
| tau Proteins | 1 | 1998 | 61 | 0.040 |
Why?
|
| Methylnitrosourea | 4 | 1983 | 9 | 0.040 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 20 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 144 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 45 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 1985 | 39 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 1991 | 142 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2018 | 146 | 0.040 |
Why?
|
| Melanoma | 1 | 2001 | 335 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2000 | 245 | 0.040 |
Why?
|
| Adult | 6 | 2014 | 21403 | 0.040 |
Why?
|
| Guanosine Diphosphate | 1 | 1997 | 12 | 0.040 |
Why?
|
| Vinca Alkaloids | 1 | 1997 | 3 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2003 | 100 | 0.040 |
Why?
|
| Guanosine Triphosphate | 1 | 1997 | 65 | 0.040 |
Why?
|
| Colchicine | 1 | 1997 | 48 | 0.040 |
Why?
|
| Transcription Factor AP-2 | 1 | 1996 | 9 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1996 | 20 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 1864 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1996 | 18 | 0.040 |
Why?
|
| Mitotic Index | 3 | 1986 | 14 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 43 | 0.040 |
Why?
|
| Algorithms | 1 | 2002 | 1196 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2550 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 304 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 1996 | 8 | 0.030 |
Why?
|
| Cytostatic Agents | 1 | 2016 | 4 | 0.030 |
Why?
|
| Insulin | 1 | 1999 | 619 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 183 | 0.030 |
Why?
|
| Etoposide | 1 | 2016 | 64 | 0.030 |
Why?
|
| Atmosphere Exposure Chambers | 1 | 2016 | 4 | 0.030 |
Why?
|
| Acrolein | 1 | 2016 | 9 | 0.030 |
Why?
|
| Quinones | 1 | 2016 | 13 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2016 | 41 | 0.030 |
Why?
|
| Phosphoramide Mustards | 2 | 1986 | 2 | 0.030 |
Why?
|
| Thiotepa | 2 | 1995 | 3 | 0.030 |
Why?
|
| Carmustine | 2 | 2000 | 14 | 0.030 |
Why?
|
| Taurine | 1 | 1996 | 51 | 0.030 |
Why?
|
| Pyruvaldehyde | 1 | 1995 | 3 | 0.030 |
Why?
|
| Peroxynitrous Acid | 1 | 2016 | 55 | 0.030 |
Why?
|
| Orosomucoid | 1 | 1995 | 5 | 0.030 |
Why?
|
| Dialysis | 1 | 1995 | 30 | 0.030 |
Why?
|
| Verapamil | 1 | 1995 | 30 | 0.030 |
Why?
|
| Buthionine Sulfoximine | 3 | 1995 | 10 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 104 | 0.030 |
Why?
|
| Isoindoles | 1 | 2014 | 9 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 243 | 0.030 |
Why?
|
| Azoles | 1 | 2014 | 7 | 0.030 |
Why?
|
| Photochemistry | 1 | 1994 | 46 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 44 | 0.030 |
Why?
|
| NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases | 1 | 1994 | 1 | 0.030 |
Why?
|
| Sequence Homology | 1 | 1994 | 11 | 0.030 |
Why?
|
| Cross-Linking Reagents | 2 | 1986 | 80 | 0.030 |
Why?
|
| Poly A | 1 | 1994 | 14 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 85 | 0.030 |
Why?
|
| Gene Library | 1 | 1994 | 68 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7029 | 0.030 |
Why?
|
| Peroxiredoxins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 455 | 0.030 |
Why?
|
| 20-Hydroxysteroid Dehydrogenases | 1 | 1993 | 1 | 0.030 |
Why?
|
| Maleates | 1 | 1993 | 7 | 0.030 |
Why?
|
| Software | 1 | 1996 | 418 | 0.030 |
Why?
|
| Macromolecular Substances | 2 | 1983 | 122 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 431 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1993 | 50 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1993 | 95 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 2083 | 0.030 |
Why?
|
| Research | 1 | 1994 | 214 | 0.030 |
Why?
|
| Skin | 2 | 1987 | 451 | 0.030 |
Why?
|
| Leukemia L1210 | 3 | 1982 | 14 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 1993 | 136 | 0.030 |
Why?
|
| Micronucleus Tests | 1 | 1992 | 3 | 0.030 |
Why?
|
| Transgenes | 1 | 2012 | 92 | 0.030 |
Why?
|
| Antibodies | 1 | 1993 | 241 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 59 | 0.030 |
Why?
|
| Filipin | 1 | 2012 | 1 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 10 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 94 | 0.030 |
Why?
|
| Foam Cells | 1 | 2012 | 26 | 0.030 |
Why?
|
| Alkaloids | 1 | 1992 | 40 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 44 | 0.030 |
Why?
|
| Bleomycin | 1 | 2012 | 67 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 52 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1992 | 67 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 173 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 160 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1992 | 88 | 0.030 |
Why?
|
| Caspases | 1 | 2012 | 194 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1991 | 15 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1992 | 77 | 0.020 |
Why?
|
| Colforsin | 1 | 1991 | 42 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 102 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 149 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 1991 | 57 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 233 | 0.020 |
Why?
|
| Mutagenesis | 1 | 1991 | 60 | 0.020 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 1991 | 19 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1991 | 20 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 1991 | 13 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1991 | 196 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1991 | 144 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2011 | 80 | 0.020 |
Why?
|
| Melphalan | 3 | 2000 | 15 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1982 | 532 | 0.020 |
Why?
|
| Glycosylation | 1 | 1991 | 185 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2012 | 157 | 0.020 |
Why?
|
| Cell Shape | 1 | 2010 | 37 | 0.020 |
Why?
|
| Semustine | 1 | 1989 | 2 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 55 | 0.020 |
Why?
|
| Deoxyribonucleases | 2 | 1980 | 8 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1990 | 78 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 507 | 0.020 |
Why?
|
| Ethylmaleimide | 1 | 1989 | 9 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2009 | 81 | 0.020 |
Why?
|
| NAD+ Nucleosidase | 2 | 1979 | 5 | 0.020 |
Why?
|
| Quinone Reductases | 1 | 1989 | 1 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1989 | 62 | 0.020 |
Why?
|
| Chemistry | 1 | 1989 | 45 | 0.020 |
Why?
|
| Leukemia, Experimental | 1 | 1989 | 14 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1988 | 73 | 0.020 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2008 | 6 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1988 | 79 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1987 | 25 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1987 | 167 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3187 | 0.020 |
Why?
|
| Lamins | 1 | 1986 | 3 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 1986 | 8 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1986 | 4 | 0.020 |
Why?
|
| Arsenates | 2 | 1996 | 5 | 0.020 |
Why?
|
| Propionates | 2 | 1996 | 21 | 0.020 |
Why?
|
| Reference Values | 1 | 1987 | 579 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1986 | 32 | 0.020 |
Why?
|
| Sister Chromatid Exchange | 1 | 1986 | 7 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1990 | 597 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 71 | 0.020 |
Why?
|
| Histones | 4 | 1979 | 111 | 0.020 |
Why?
|
| Quinolines | 2 | 1996 | 48 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 134 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 144 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1986 | 223 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 122 | 0.020 |
Why?
|
| Pigments, Biological | 1 | 1985 | 15 | 0.020 |
Why?
|
| Phosphodiesterase I | 1 | 1985 | 3 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 1985 | 16 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 1985 | 6 | 0.020 |
Why?
|
| Chromatography, Thin Layer | 1 | 1985 | 52 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1985 | 22 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2006 | 190 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1985 | 155 | 0.020 |
Why?
|
| Adenosine Monophosphate | 1 | 1985 | 41 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 3 | 1996 | 532 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1986 | 202 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1991 | 1026 | 0.010 |
Why?
|
| Temperature | 1 | 1985 | 341 | 0.010 |
Why?
|
| Ribonucleoproteins | 1 | 1983 | 19 | 0.010 |
Why?
|
| Sulfur | 1 | 2004 | 16 | 0.010 |
Why?
|
| Survival Analysis | 2 | 1998 | 714 | 0.010 |
Why?
|
| Receptors, Estradiol | 1 | 1983 | 1 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1851 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5717 | 0.010 |
Why?
|
| Hydroxybenzoates | 1 | 2002 | 9 | 0.010 |
Why?
|
| Karyotyping | 1 | 1982 | 74 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1982 | 78 | 0.010 |
Why?
|
| Flavonoids | 1 | 2002 | 109 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 8912 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1980 | 25 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1980 | 149 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2002 | 358 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1980 | 13 | 0.010 |
Why?
|
| Magnesium | 1 | 1980 | 110 | 0.010 |
Why?
|
| Thioredoxins | 1 | 1999 | 26 | 0.010 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1979 | 8 | 0.010 |
Why?
|
| Ubiquitins | 1 | 1999 | 22 | 0.010 |
Why?
|
| Micrococcal Nuclease | 1 | 1978 | 7 | 0.010 |
Why?
|
| Subrenal Capsule Assay | 1 | 1998 | 3 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1999 | 130 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1980 | 206 | 0.010 |
Why?
|
| Photoaffinity Labels | 1 | 1998 | 7 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1980 | 649 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1998 | 294 | 0.010 |
Why?
|
| Spleen | 1 | 1978 | 301 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1996 | 49 | 0.010 |
Why?
|
| Leukotriene Antagonists | 1 | 1996 | 13 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 95 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 165 | 0.010 |
Why?
|
| Pyrazoles | 1 | 1996 | 190 | 0.010 |
Why?
|
| Diuresis | 1 | 1994 | 20 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1994 | 260 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1996 | 511 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 52 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1992 | 53 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 47 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 1992 | 138 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 1992 | 128 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1992 | 328 | 0.010 |
Why?
|
| Ovary | 1 | 1991 | 99 | 0.010 |
Why?
|
| Nimustine | 1 | 1990 | 1 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1990 | 76 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1990 | 284 | 0.010 |
Why?
|
| Interphase | 1 | 1987 | 19 | 0.000 |
Why?
|
| Vimentin | 1 | 1987 | 47 | 0.000 |
Why?
|
| Epithelium | 1 | 1987 | 172 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1985 | 17 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1982 | 120 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1982 | 181 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1976 | 57 | 0.000 |
Why?
|
| Metabolism | 1 | 1976 | 12 | 0.000 |
Why?
|
| Folic Acid Antagonists | 1 | 1976 | 20 | 0.000 |
Why?
|
| Folic Acid | 1 | 1976 | 123 | 0.000 |
Why?
|